Theravance Biopharma TBPH Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's operating lease liabilities?
- Theravance Biopharma (TBPH) reported operating lease liabilities of $29.75M in Q1 2026.
- How has Theravance Biopharma's operating lease liabilities changed year-over-year?
- Theravance Biopharma's operating lease liabilities decreased by 20.3% year-over-year, from $37.35M to $29.75M.
- What is the long-term trend for Theravance Biopharma's operating lease liabilities?
- Over 5 years (2020 to 2025), Theravance Biopharma's operating lease liabilities has grown at a -7.6% compound annual growth rate (CAGR), from $47.22M to $31.76M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.